A Phase 3 clinical trial, INTELLANCE-1, evaluating AbbVie's (NYSE:ABBV) antibody-drug conjugate (ADC) depatuxizumab mafodotin (Depatux-M, previously named ABT-414) in patients with newly diagnosed EGFR-positive glioblastoma failed to demonstrate a survival benefit, the primary endpoint.
The study was investigating the potential treatment effect of Depatux-M when added to standard-of-care (SOC) therapy of radiation and temozolomide versus placebo + SOC.
Based on its analysis of the preliminary data, an independent Data Monitoring Committee has recommended the termination of the study. The company has stopped enrollment.
AbbVie in-licensed the ADC technology from Seattle Genetics (NASDAQ:SGEN).
Shares are down 2% premarket on light volume. SGEN is down a fraction.
Subscribe for full text news in your inbox